摘要
目的评价匹多莫德对毛细支气管炎患儿Th1、Th2细胞因子的影响。方法选择90例毛细支气管炎患儿，随机分为治疗组和对照组，每组各45例。对照组予常规抗感染、雾化平喘等对症治疗。治疗组在对照组治疗基础上加用匹多莫德口服液（意大利多帕药业有限公司生产，每支400mg）急性感染期（7～10d）每次400mg，每日2次；急性感染期后每次400mg，每日1次。检测外周静脉血Th1／Th2细胞因子比值的变化。结果两组治疗前后Th1／Th2细胞因子比值变化，治疗前两组Th1／Th2比值基本一致（P〉0．05）；治疗后治疗组Th1／Th2比值明显升高（P〈0．01），对照组则变化不明显（P〉0．05）。两组间比较差别明显（P〈0．01）。结论匹多莫德能通过调整Th1、Th2细因子间平衡，增强了机体的细胞免疫功能，有利于毛细支气管炎患儿的恢复，临床疗效确切，安全性高，值得推广。
Objective To investigate the effect of pidotimod Th1/Th2 cytokines in children with capillary bronchitis. Methods 90 children with capillary bronchitis were randomly divided into treatment group and control group with 45 children in each group. In the control group, children received routine therapy including anti-infection and anti-asthmas for 3 months while the subjects in treatment group received pidotimod （specification： 400 mg /tablets） besides routine treatments. The levels of Th1/Th2 had been detected. Results Compared with control group, the ratio of Th1/Th2 showed no differences before treatment （ P 〉0.05）, however, the ratio increased apparently after treatment （ P 〈0.0 1）, and the clinical efficacy in treatment was significantly better than that in control group （P 〈 0.05）. Conclusions Pidotimod has better curative effect to children with capillary bronchitis related to modulating the balance of Th1/Th2.
出处
《国际呼吸杂志》
2012年第23期1771-1773,共3页
International Journal of Respiration
